NCT06149286: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 3 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06149286 |
|---|---|
| Title | A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 28, 2023 |
| Completion date | Jan. 23, 2029 |
| Required reporting date | Jan. 23, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |